- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02212522
Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications (ISIS-DIAB)
Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications. French Multicentric Cohort of Diabetic Patients.
The aim of this study is to complete the identification of genetic factors (G) and to undertake the search of environmental factors (E) predisposing to type 1 diabetes (T1D) by constituting a cohort of 3500 T1D patients and a control cohort. We will use the base of G analysis (whole genome genotyping done once a patient using methods conually updated at Centre National de Genotype) and innovative E analysis to develop the following long term objectives :
- Identify G and E factors influencing the process of remaining beta cells' destruction during the first 3 years after diagnosis (subgroup of T1D patients with a 0-3 years diabetes duration);
- Identify G factors (pharmacogenomics) of the individual response to insulin using the effective insulin dose as a phenotype over a period of 2 years (subgroup of T1D patients with negative C-peptide and well managed diabetes);
- Undertake a prospective research of G and E risk factors of "death in bed" syndrome in diabetic adolescents;
- Undertake a prospective research of G and E risk factors of incipient glomerular microangiopathy (regule measurement of microalbuminuria).
Studieoversigt
Status
Betingelser
Intervention / Behandling
- Andet: Collect of environmental data on T1D patients before diagnosis
- Genetisk: Collect of blood samples for DNA extraction and genetic characterization (GWAS)
- Andet: Collect of clinical data on the disease and its evolution
- Andet: Collect of environmental data on French controls (age-matched for T1D patients)
Detaljeret beskrivelse
Still recognized in youth only at a stage of complete beta-cell mass destruction and insulin deficiency, autoimmune T1D remains a source of major morbidity through daily life and chronic angiopathic complications despite a better glycemic control. T1D onset is now predominantly pediatric, since its incidence shows a rapid and continuous increase in young European children, due to unknown emerging environmental changes, creating a major need for discoveries in the environmental field. Finding avoidable E factors can allow T1D prevention in the whole children population. Lack of infectious exposures ("the hygiene hypothesis"), viruses, early nutrition, or other factors have been suspected, but E causes of T1D remain a black box, as for most human diseases, that should now be approached more systematically and with respect to gene-environment interactions.
The aim of our study is to complete the identification of genetic factors (G) and to undertake the search of environmental factors (E) predisposing to type 1 diabetes (T1D) by constituting a cohort of 3500 T1D patients and a control cohort. We will use the base of G analysis (whole genome genotyping done once a patient using methods conually updated at Centre National de Genotype) and innovative E analysis to develop the following long term objectives :
- Identify G and E factors influencing the process of remaining beta cells' destruction during the first 3 years after diagnosis (subgroup of T1D patients with a 0-3 years diabetes duration);
- Identify G factors (pharmacogenomics) of the individual response to insulin using the effective insulin dose as a phenotype over a period of 2 years (subgroup of T1D patients with negative C-peptide and well managed diabetes);
- Undertake a prospective research of G and E risk factors of "death in bed" syndrome in diabetic adolescents;
- Undertake a prospective research of G and E risk factors of incipient glomerular microangiopathy (regule measurement of microalbuminuria).
We propose to constitute a French multicentric cohort of T1D patients, well phenotyped by 3 data types : genetic, environmental and clinical data. The data collection scheme includes at entry a comprehensive 850 items environmental questionnaire for all subjects and a full genotyping with at least 500,000 SNPs until whole-genome sequencing can be deployed by CNG-CEA. Every 6 months, a standardized clinical assessment is made in patients (a WEB application ensuring this standardization has already been developed). Personal address(es) will be collected and geocoded, then mapped with environmental geographic information systems (GIS).
With environmental modelling, the high dimensionality analyses (HDA) constitutes one of the main originality of ISIS-DIAB approaches of translational research. HDA will face not only a massive mass of data, but data of a remarkable diversity (genomic variants, environmental items from questionnaires, environmental data bases mapped to patient address, space-time items, characteristics of social environment, clinical phenotypes etc). A given genotype (defined by many genomic variants) will predispose to T1D only in a given environmental context (defined possibly by a number of factors) and induce a given type of autoimmune process (age of onset, rate of destruction, biomarkers). Since T1D is both multifactorial and heterogeneous, causal factors may interact in a considerable number of scenarii, thus platforms which study these factors should obviously interact. Without HDA, each platform would be left faced with its own data. The chef d'orchestre has to be HDA, to integrate the massive amounts of data and draw networks of causality. Technological advances in HDA developed in other fields of sciences, business and economics (forecasting technology) will be transferred to biomedical research through ISIS-DIAB. French have a strong tradition of high-level maths in this area. We designed the ISIS-DIAB cohort and collection of data to feed HDA with multidisciplinary data. In ISIS-DIAB program, HDA will identify the variables that have the most predictive value on several outcomes (not confined to T1D causality).
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiekontakt
- Navn: Sophie Le Fur, PhD
- Telefonnummer: +33 1 49 59 53 43
- E-mail: sophie.le-fur@inserm.fr
Undersøgelse Kontakt Backup
- Navn: Laurence Lecomte, PhD
- Telefonnummer: +33 1 71 19 64 94
- E-mail: laurence.lecomte@nck.aphp.fr
Studiesteder
-
-
-
Le Kremlin Bicêtre, Frankrig, 94276
- Rekruttering
- Inserm U986
-
Kontakt:
- Sophie Le Fur, PhD
- Telefonnummer: + 33 1 49 59 53 43
- E-mail: sophie.le-fur@inserm.fr
-
Kontakt:
- Laurence Lecomte, PhD
- Telefonnummer: +33 1 71 19 64 94
- E-mail: laurence.lecomte@nck.aphp.fr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients: T1D patients are enrolled into the Isis-Diab cohort, continuously, from 110 clinical diabetes centers distributed over the whole France territory. Inclusion in the cohort occurs most often soon after the initial diagnosis of T1D. This diagnosis is made according to classical criteria of autoimmune T1D.
Controls: we will recruit age-matched controls among friend patients' families and among cases admitted in the participating centers for benign transient intercurrent events.
Beskrivelse
Inclusion Criteria:
- Insulin-dependent diabetes
- Patients older than 6 months at inclusion
- European or North African geographical origin (defined by the birthplaces of the 4 grandparents), for the purpose of genetic homogeneity of the cohort
- Anti-GAD, IA2, and insulin autoantibodies, that are present only in the first year of the disease evolution, are not a criterion of absolute inclusion (low risk of error) but will be noted if they were searched at diagnosis
- Informed consent dated and voluntarily signed (patient and/or parents)
Exclusion Criteria:
- Non-insulin dependent diabetes
- MODY
- Severe psychological problems, co-morbidities that could possibly invalidate informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Isis-Diab patients
French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
|
Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
Collect of clinical data on the disease and its evolution every 6 months after enrollment
|
Isis-Diab controls
French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
|
Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Genetic and environmental risk factors of T1D predisposition
Tidsramme: 10 years
|
10 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Genetic and environmental risk factors of T1D complications
Tidsramme: 10 years
|
Regular measurement of microalbuminuria
|
10 years
|
Identify G and E factors influencing the process of remaining beta cells' destruction during the first 3 years after diagnosis
Tidsramme: 5 years
|
Subgroup of T1D patients with a 0-3 years diabetes duration
|
5 years
|
Identify G factors (pharmacogenomics) of the individual response to insulin using the effective insulin dose as a phenotype over a period of 2 years
Tidsramme: 4 years
|
Subgroup of T1D patients with negative C-peptide and well managed diabetes
|
4 years
|
Undertake a prospective research of G and E risk factors of "death in bed" syndrome in diabetic adolescents
Tidsramme: 5 years
|
5 years
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Pierre BOUGNERES, MD-PhD, Inserm U986/ Pediatric endocrinology department of the Bicêtre hospital
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- AOM 08049
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsAfsluttetDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater